drugset / Trial / NCT00038168
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not responded to hormone treatment. A second goal is to find out if the side effects of these drugs can be reversed. The safety of these drugs will also be studied.
Timeline
- Start
- 2000-06
- Primary completion
- 2003-01
- Completion
- 2003-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | estramustine | Other / unclassified | — | Intravenous |